The shorter, the better: A review of the evidence for a shorter contraceptive hormone-free interval

Alessandra Graziottin
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception · 2015 · vol. 21(2) , pp. 93–105 · doi:10.3109/13625187.2015.1077380 · PMID:26291185 · W1812059618
Review OA: closed CC0 ⤵ 15 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Shortening the hormone-free interval in combined oral contraceptives, particularly with a 26/2 regimen, reduces menstrual symptoms and improves women's quality of life by decreasing inflammatory processes.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVES: The menstrual cycle is characterised by cyclical fluctuations in oestrogens, progesterone and androgens. Changes in hormone levels in the premenstrual phase with the decline in progesterone trigger a physiological reaction which culminates in menstruation. This process is accompanied in many women by various symptoms such as pelvic pain, headache, mood disorders and gastrointestinal discomfort. The aim of this article was to summarise the latest findings on the physiology and pathophysiology of menstruation and review the impact of shortening the hormone-free interval (HFI) on the health and wellbeing of women. RESULTS: Menstruation can be viewed as an inflammatory event in which local and systemic effects produce symptoms in genital and extragenital regions of the body. The mast cells are the main mediator of this reaction. In women using hormonal contraceptives, menstrual bleeding is not biologically necessary and it may be advantageous to maintain more stable levels of oestrogens, progesterone and androgens throughout the cycle. New combined oral contraceptives (COCs) have been formulated with a progressively shorter HFI (24/4 and 26/2) than traditional 21/7 pills, with the rationale of reducing hormone withdrawal- associated symptoms. Several studies have shown the beneficial effects of these regimens, which reduce the inflammatory exposure of the female organism and thus have the capacity to increase the quality of life of women. A combination of estradiol valerate (E2V) and dienogest (DNG) is administered on the shortest 26/2 regimen. This regimen has a broad evidence base from randomised controlled trials that have examined the impact of E2V/DNG on symptoms and quality of life. CONCLUSIONS: Shortening the HFI reduces the occurrence of bleeding-related inflammatory processes and subsequent physical and mental symptoms. The shortest interval with evidence of reproductive and sexual health benefits is provided by a 26/2 regimen.

My notes (saved in your browser only)

MeSH descriptors

Contraceptives, Oral, Combined Contraceptives, Oral, Hormonal Dysmenorrhea Gastrointestinal Diseases Headache Inflammation Menstruation Mood Disorders Pelvic Pain Quality of Life Contraceptives, Oral, Combined Contraceptives, Oral, Hormonal Drug Administration Schedule Drug Combinations Dysmenorrhea Dysmenorrhea Estradiol Estradiol Estradiol Estrogens

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (68)

Cited by (11)

Source provenance

openalex
last seen: 2026-05-11T06:18:49.075943+00:00
pubmed
last seen: 2026-10-08T21:16:08.491429+00:00
unpaywall
last seen: 2026-10-13T06:25:51.201866+00:00
License: CC0 · commercial use OK